Eligibility

You'll find all of our eligibility information on this page.

Who we register

The BAD Biologic and Immunomodulators Register now has three psoriasis patient cohorts; one for patients receiving biologic therapy, a second for patients being treated with conventional anti-psoriatic systemics, and a new, third cohort for patients receiving small molecule therapies.

To be eligible to join BADBIR, patients must be receiving a drug for therapy of their psoriasis that we currently recruit for, and meet the other criteria set out below.

Biologic cohort

  • The patient must have started or switched to a biologic therapy within six months of registration on the database. This therapy must be ongoing at the time of patient consent.
  • The biologic therapies we recruit for are:
    • Amgevita (Adalimumab biosimilar) - NEW
    • Benepali (Etanercept biosimilar)
    • Cimzia (Certolizumab pegol)
    • Cosentyx (Secukinumab)
    • Erelzi (Etanercept biosimilar)
    • Humira (Adalimumab)
    • Hyrimoz (Adalimumab biosimilar) - NEW
    • Kyntheum (Brodalumab)
    • Stelara (Ustekinumab)
    • Taltz (Ixekizumab)
    • Tremfya (Guselkumab) - NEW
    • Zessly (Infliximab biosimilar) - NEW
  • Unlike conventional patients, there is no PASI/DLQI minimum requirement, as it is assumed that the patient's psoriasis is of a reasonable severity as they are commencing a biologic therapy.
  • Consent must be provided by the patient to join BADBIR.
  • Please note that although there is no minimum PASI or DLQI score for biologic patients, we still need scores taken within six months prior to the patient commencing their treatment so we have a baseline disease severity measure.

Non-Biologic Small Molecule cohort

  • The patient must have started or switched to a non-biologic small molecule therapy within six months of registration on the database. This therapy must be ongoing at the time of patient consent.
  • The non-biologic small molecule therapies we recruit for are:
    • Otezla (apremilast) - NEW
  • The patient must be naïve to biologic therapy.
  • Consent must be provided by the patient to join BADBIR.
  • Please note although there is no minimum PASI or DLQI score for non-biologic small molecule cohort patients, we still need scores taken within six months prior to the patient commencing their treatment so we have a baseline disease severity measure.

Conventional cohort

  • The patient must have started or switched to a conventional therapy within six months of registration on the database. This therapy must be ongoing at the time of patient consent.
  • The conventional therapies we recruit for are:
    • Acitretin
    • Ciclosporin
    • Fumaric acid esters
    • Hydroxycarbamide
    • Methotrexate
    • Systemic oral PUVA - please note we don't recruit for bath PUVA
  • The patient's PASI at the time the drug is started must be greater than or equal to 10 (10 or more), and the DLQI greater than 10 (11 or more). This does not apply if the patient is switching between conventional therapies, or if the patient has an ongoing conventional treatment and is being registered on a new one alongside this.
  • The patient must be naïve to biologic therapy.
  • Consent must be provided by the patient to join BADBIR.

Please contact the BADBIR office to discuss specific eligibility if you are unsure.